FINANCIAL REVIEW

We are excited to share our 2024 annual report!

Delivering on expectations and investing in the future Ferrosan Medical Devices delivered solid operational and financial results again in 2024, which was characterized by a high activity level and continued growth in our hemostatic product portfolio combined with accelerated investments in people and production capabilities. In 2025, we expect to continue to develop and grow our business driven by underlying market growth fueled by an increase in surgical procedures as access to care increases and from market expansions.

Revenue in millions

2018
539.4
2019
528.1
2020
622.4
2021
720.4
2022
810.3
2023
893,4
2024
997

Full-time equivalent employees

2018
269
2019
287
2020
329
2021
345
2022
360
2023
379
2024
437

News

Search

CLOSE
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors